In this concluding segment, Dr. Shore will share clinical pearls and practical insights regarding the optimal management of patients with metastatic hormone-sensitive prostate cancer.
Ready-to-Use 3-Month Leuprolide Depot Formulation Nears FDA Approval
A new drug application for a 3-month depot formulation of leuprolide mesylate has been submitted to the FDA.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
FDA Provides Positive Feedback on AMPLIFY Trial for Prostate Cancer Diagnostic
The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately 220 patients with prostate cancer with biochemical recurrence.
A Deep Dive Into the Evolving Landscape of Prostate Cancer
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Talazoparib/Enzalutamide Combo Offers Significant Survival Benefits in Prostate Cancer
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.
FDA Oks Aquablation vs Prostatectomy Trial in Localized Prostate Cancer
The FDA has approved the WATER IV PCa trial, which will compare the safety and efficacy of Aquablation therapy to radical prostatectomy in patients with localized prostate cancer.